Therapeutic Antibody Against Phosphorylcholine Preserves Coronary Function and Attenuates Vascular 18F-FDG Uptake in Atherosclerotic Mice

• Published in: JACC. Basic to translational science 2020-04, Vol.5 (4), p.360-373
• Main Authors: Ståhle, Mia, Silvola, Johanna M.U., Hellberg, Sanna, de Vries, Margreet, Quax, Paul H.A., Kroon, Jeffrey, Rinne, Petteri, de Jong, Alwin, Liljenbäck, Heidi, Savisto, Nina, Wickman, Anna, Stroes, Erik S.G., Ylä-Herttuala, Seppo, Saukko, Pekka, Abrahamsson, Tommy, Pettersson, Knut, Knuuti, Juhani, Roivainen, Anne, Saraste, Antti
• Format: Article
• Language: English
• Subjects: 18F-fluorodeoxyglucose positron emission tomography; atherosclerosis; coronary flow reserve; inflammation; phosphorylcholine; PRECLINICAL RESEARCH
• ISSN: 2452-302X; 2452-302X
• DOI: 10.1016/j.jacbts.2020.01.008

[Display omitted] •Phosphorylcholine is a pro-inflammatory epitope in atherogenic oxidized phospholipids.•This study investigated effects of a novel monoclonal IgG1 antibody against PC on vascular function and atherosclerotic inflammation.•Treatment with phosphorylcholine antibody preserved coronary flow reserve and decreased uptake of 18F-FDG in atherosclerotic lesions in hypercholesterolemic mice.•Noninvasive imaging techniques represent translational tools to assess the efficacy of phosphorylcholine-targeted therapy on coronary artery function and atherosclerosis. This study showed that treatment with a therapeutic monoclonal immunoglobulin-G1 antibody against phosphorylcholine on oxidized phospholipids preserves coronary flow reserve and attenuates atherosclerotic inflammation as determined by the uptake of 18F-fluorodeoxyglucose in atherosclerotic mice. The noninvasive imaging techniques represent translational tools to assess the efficacy of phosphorylcholine-targeted therapy on coronary artery function and atherosclerosis in clinical studies.